A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT04064827 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Company Decision

Conditions

Chronic Kidney Disease (CKD)
Secondary Hyperparathyroidism (SHPT)

Interventions

DRUG: Paricalcitol

Sponsor

AbbVie